Blood products and vaccine provider CSL has lifted its profit 19 per cent amid stronger sales and improved margins.

CSL made a net profit of $US1.22 billion ($A1.35 billion) for the 2012/13 financial year, up from $1.02 billion for the previous year.

Revenue was $US5.13 billion, up from $US4.81 billion for the previous 12 months.

CSL chief executive officer Paul Perreault said the company had lifted sales and improved margins on its key products during the year.

“The company’s core products of immunoglobulin and albumin have performed very well and we have strengthened our margins through a change in sales mix and a relentless pursuit of efficiency,” he said.

“Our suite of specialty products grew strongly, supported by the registration in the US of Kcentra, a product used in the urgent reversal of anticoagulant warfarin in patients with acute major bleeding.”